JP6672264B2 - 過眠症を治療するための方法 - Google Patents

過眠症を治療するための方法 Download PDF

Info

Publication number
JP6672264B2
JP6672264B2 JP2017506256A JP2017506256A JP6672264B2 JP 6672264 B2 JP6672264 B2 JP 6672264B2 JP 2017506256 A JP2017506256 A JP 2017506256A JP 2017506256 A JP2017506256 A JP 2017506256A JP 6672264 B2 JP6672264 B2 JP 6672264B2
Authority
JP
Japan
Prior art keywords
ptz
subject
pharmaceutical composition
administered
hypersomnia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017506256A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511386A5 (enExample
JP2017511386A (ja
Inventor
リエン，リンドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Balance Therapeutics, Inc.
Original Assignee
Balance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balance Therapeutics, Inc. filed Critical Balance Therapeutics, Inc.
Publication of JP2017511386A publication Critical patent/JP2017511386A/ja
Publication of JP2017511386A5 publication Critical patent/JP2017511386A5/ja
Application granted granted Critical
Publication of JP6672264B2 publication Critical patent/JP6672264B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017506256A 2014-04-15 2015-04-14 過眠症を治療するための方法 Expired - Fee Related JP6672264B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461979918P 2014-04-15 2014-04-15
US61/979,918 2014-04-15
PCT/US2015/025696 WO2015160766A1 (en) 2014-04-15 2015-04-14 Methods for treating hypersomnia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020036646A Division JP2020105200A (ja) 2014-04-15 2020-03-04 過眠症を治療するための方法

Publications (3)

Publication Number Publication Date
JP2017511386A JP2017511386A (ja) 2017-04-20
JP2017511386A5 JP2017511386A5 (enExample) 2018-06-07
JP6672264B2 true JP6672264B2 (ja) 2020-03-25

Family

ID=54324484

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017506256A Expired - Fee Related JP6672264B2 (ja) 2014-04-15 2015-04-14 過眠症を治療するための方法
JP2020036646A Pending JP2020105200A (ja) 2014-04-15 2020-03-04 過眠症を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020036646A Pending JP2020105200A (ja) 2014-04-15 2020-03-04 過眠症を治療するための方法

Country Status (12)

Country Link
US (3) US10688103B2 (enExample)
EP (1) EP3131904A4 (enExample)
JP (2) JP6672264B2 (enExample)
KR (1) KR20170005415A (enExample)
CN (1) CN106459066B (enExample)
AU (2) AU2015247829B2 (enExample)
CA (1) CA2945705A1 (enExample)
EA (1) EA201692061A1 (enExample)
IL (1) IL248255A0 (enExample)
MX (1) MX2016013340A (enExample)
WO (1) WO2015160766A1 (enExample)
ZA (1) ZA201607068B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
US11529358B2 (en) 2017-05-10 2022-12-20 Emory University Treatment of conditions associated with myotonic dystrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137746A (ja) 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
CA2686155C (en) 2006-05-22 2016-11-15 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
JP2010515882A (ja) * 2007-01-05 2010-05-13 アリーナ ファーマシューティカルズ， インコーポレイテッド 睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子
US9616070B2 (en) * 2008-03-12 2017-04-11 Emory University Use of GABAA receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US8946206B2 (en) * 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
JP2014511382A (ja) 2011-02-23 2014-05-15 コエルルウス リミテッド フルマゼニル錯体、それを含む組成物、およびその使用
ES2579319T3 (es) 2011-05-04 2016-08-09 Balance Therapeutics, Inc. Derivados de pentilenotetrazol

Also Published As

Publication number Publication date
US10688103B2 (en) 2020-06-23
AU2019268190A1 (en) 2019-12-12
EA201692061A1 (ru) 2017-03-31
KR20170005415A (ko) 2017-01-13
US20180169107A1 (en) 2018-06-21
ZA201607068B (en) 2023-01-25
WO2015160766A1 (en) 2015-10-22
IL248255A0 (en) 2016-11-30
EP3131904A1 (en) 2017-02-22
CN106459066B (zh) 2020-07-07
EP3131904A4 (en) 2017-11-22
AU2015247829A1 (en) 2016-10-27
CN106459066A (zh) 2017-02-22
MX2016013340A (es) 2017-02-09
JP2017511386A (ja) 2017-04-20
JP2020105200A (ja) 2020-07-09
US20200360398A1 (en) 2020-11-19
AU2015247829B2 (en) 2019-12-05
CA2945705A1 (en) 2015-10-22
US20230115839A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
US10912754B2 (en) Methods and compositions for treating excessive sleepiness
US9789119B2 (en) Cognitive function
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EP3920898B1 (en) Methods and compositions for treating sleep apnea
US20230115839A1 (en) Methods For Treating Hypersomnia
KR20200146038A (ko) 환각 및 이와 관련된 상태를 치료하는 방법 및 조성물
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
US20240316057A1 (en) Pulsatile release caffeine formulation
JP6738797B2 (ja) レット症候群治療薬
WO2025257142A1 (en) Fasudil for use in treating amyotrophic lateral sclerosis
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
HK40065333B (en) Methods and compositions for treating sleep apnea
JPWO2005027968A1 (ja) ダウン症候群治療剤
CN101827597A (zh) 睡眠障碍的治疗
Tremor NEUROLOGICAL SLEEP DISORDERS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200304

R150 Certificate of patent or registration of utility model

Ref document number: 6672264

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees